AU756677B2 - Anti-TNFalpha antibodies in therapy of asthma - Google Patents

Anti-TNFalpha antibodies in therapy of asthma Download PDF

Info

Publication number
AU756677B2
AU756677B2 AU33861/00A AU3386100A AU756677B2 AU 756677 B2 AU756677 B2 AU 756677B2 AU 33861/00 A AU33861/00 A AU 33861/00A AU 3386100 A AU3386100 A AU 3386100A AU 756677 B2 AU756677 B2 AU 756677B2
Authority
AU
Australia
Prior art keywords
antibody
tnfa
asthma
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33861/00A
Other languages
English (en)
Other versions
AU3386100A (en
Inventor
George Treacy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of AU3386100A publication Critical patent/AU3386100A/en
Application granted granted Critical
Publication of AU756677B2 publication Critical patent/AU756677B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU33861/00A 1999-03-02 2000-03-01 Anti-TNFalpha antibodies in therapy of asthma Ceased AU756677B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26095399A 1999-03-02 1999-03-02
US09/260953 1999-03-02
US46569199A 1999-12-17 1999-12-17
US09/465691 1999-12-17
PCT/US2000/005163 WO2000051637A1 (en) 1999-03-02 2000-03-01 ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA

Publications (2)

Publication Number Publication Date
AU3386100A AU3386100A (en) 2000-09-21
AU756677B2 true AU756677B2 (en) 2003-01-23

Family

ID=26948290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33861/00A Ceased AU756677B2 (en) 1999-03-02 2000-03-01 Anti-TNFalpha antibodies in therapy of asthma

Country Status (10)

Country Link
US (3) US20010021381A1 (https=)
EP (1) EP1159003B1 (https=)
JP (2) JP2002538170A (https=)
AT (1) ATE488250T1 (https=)
AU (1) AU756677B2 (https=)
CA (1) CA2364026C (https=)
DE (1) DE60045240D1 (https=)
DK (1) DK1159003T3 (https=)
PT (1) PT1159003E (https=)
WO (1) WO2000051637A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060251656A1 (en) * 2003-02-11 2006-11-09 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
CA2827609A1 (en) * 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
EP3194439B1 (en) * 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN115804821B (zh) * 2022-12-19 2024-05-14 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6309640B1 (en) * 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4822776A (en) * 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6419927B1 (en) * 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1857553A1 (en) * 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
DE4139733A1 (de) * 1991-11-28 1993-06-03 Schering Ag Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren
CA2146647C (en) * 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
DE69427928T3 (de) * 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
CN1178955C (zh) * 1997-04-15 2004-12-08 法默卡有限公司 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
EP0980258A1 (en) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases

Also Published As

Publication number Publication date
WO2000051637A1 (en) 2000-09-08
US20020119152A1 (en) 2002-08-29
EP1159003B1 (en) 2010-11-17
CA2364026A1 (en) 2000-09-08
DK1159003T3 (da) 2011-02-07
PT1159003E (pt) 2011-02-22
JP2011006464A (ja) 2011-01-13
US20010021381A1 (en) 2001-09-13
EP1159003A1 (en) 2001-12-05
CA2364026C (en) 2012-08-21
DE60045240D1 (de) 2010-12-30
JP2002538170A (ja) 2002-11-12
US20060222646A1 (en) 2006-10-05
AU3386100A (en) 2000-09-21
ATE488250T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
AU756677B2 (en) Anti-TNFalpha antibodies in therapy of asthma
JP4970258B2 (ja) ヒトインターロイキン−１３に対する抗体およびそれらの使用
KR101004353B1 (ko) 다양한 질환의 치료에 유용한 항-엔지에프 항체
US7501121B2 (en) IL-13 binding agents
AU2005327240B2 (en) IL-13 binding agents
KR101605861B1 (ko) Ｉｌ－２５에 대한 항체
RU2640025C2 (ru) Способы и композиции для лечения астмы с использованием антител против il-13
KR20020073178A (ko) 인간 ＩＬ-1β에 대한 항체
AU2001295490A1 (en) Antibodies to human IL-1beta
WO2001037874A2 (en) Treatment of psoriasis by using an antibody to tnf alpha
ES2357749T3 (es) Anticuerpos anti-tnf alfa en la terapia del asma resistente a esteroides.
NZ619873B2 (en) Methods and compositions for treating asthma using anti-il-13 antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired